Floatz logo

Emzadirib

Soft Tissue Sarcoma

Cyteir Therapeutics, Inc.Small moleculePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
81/ 100

Competitive context

104 Active assets in the Soft Tissue Sarcoma cohort.

Asset / SponsorPhaseRating
Palbociclib
Brown University
Phase 2BB
Inno-206
GI Innovation, Inc.
Phase 3BB
Eloxatin
OHSU Knight Cancer Institute
Phase 2BB
FILGRASTIM
University of California, Irvine
Phase 3BB
Cyclophosphamide
St. Jude Children's Research Hospital
Phase 2BB

View all 50 →

Same molecule, other indications

Emzadirib is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
CCC
Indicative ·
50 / 100
View asset →
diffuse large B-cell lymphomaDormant
CCC
Indicative ·
50 / 100
View asset →
cancerDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →